



















**Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]**  
Disclosure of related party transactions for the half year/ six months ended September 30, 2023

Amount in INR Million except stated otherwise

S. No.	Details of the party entering into the transaction		Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans/ investments				Details of loans/ investments			
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Nature of indebtedness [Loans/ issuance of debt/ any other]						Opening balance	Closing balance	Nature of indebtedness	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured
80	Zydus Lifesciences Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-	-	-	-	-	-	-	-	
81	Zydus Lifesciences Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-	-	-	-	-	-	-	-	
82	Zydus Lifesciences Limited	Mrs. Upasana Konidela	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-	-	-	-	-	-	-	-	
83	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Remuneration		-	N.A.	123	-	-	-	-	-	-	-	-	-	-	
84	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Remuneration		-	N.A.	61	-	-	-	-	-	-	-	-	-	-	
85	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Remuneration		-	N.A.	42	-	-	-	-	-	-	-	-	-	-	
86	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-	-	-	-	-	-	-	-	
87	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-	-	-	-	-	-	-	-	-	
88	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.	353	-	-	-	-	-	-	-	-	-	-	
89	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.	396	-	-	-	-	-	-	-	-	-	-	
90	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.	37	-	-	-	-	-	-	-	-	-	-	
91	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.	388	-	-	-	-	-	-	-	-	-	-	
92	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Interest received		-	N.A.	2	-	-	-	-	-	-	-	-	-	-	
93	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Interest paid		-	N.A.	39	-	-	-	-	-	-	-	-	-	-	
94	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Interest paid		-	N.A.	892	-	-	-	-	-	-	-	-	-	-	
95	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.	745	-	-	-	-	-	-	-	-	-	-	
96	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.	824	-	-	-	-	-	Loan	6 Month SOFR + 80 bps	5 Year	Unsecured	Business Purpose	
97	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Investment		-	N.A.	5,700	-	5,700	-	-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
98	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Investment		-	N.A.	2,950	-	2,950	-	-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
99	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Investment		-	N.A.	21	-	21	-	-	-	Investment	N.A	N.A	Unsecured	Business Purpose	
100	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Investment		-	N.A.	198	-	198	-	-	-	Investment	N.A	N.A	Unsecured	Business Purpose	































**Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]**  
Disclosure of related party transactions for the half year/ six months ended September 30, 2023

Amount in INR Million except stated otherwise

S. No.	Details of the party entering into the transaction								In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans/ investments				Details of loans/ investments			
	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
	Name	Name																
293	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services	-	N.A.	457	-	-	-	-	-	-	-	-	-	-	-
294	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services	-	N.A.	3	-	-	-	-	-	-	-	-	-	-	-
295	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services	-	N.A.	2	-	-	-	-	-	-	-	-	-	-	-
296	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services	-	N.A.	2	-	-	-	-	-	-	-	-	-	-	-
297	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimbursement of Expenses paid	-	N.A.	10	-	-	-	-	-	-	-	-	-	-
298	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	1	-	-	-	-	-	-	-	-	-	-
299	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	1	-	-	-	-	-	-	-	-	-	-
300	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	3	-	-	-	-	-	-	-	-	-	-
301	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	1	-	-	-	-	-	-	-	-	-	-
302	Zydus Pharmaceuticals (USA) Inc.	Zydus Noveltech Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	0	-	-	-	-	-	-	-	-	-	-
303	Zydus Pharmaceuticals (USA) Inc.	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	0	-	-	-	-	-	-	-	-	-	-
304	Zydus Pharmaceuticals (USA) Inc.	Mahadev Management Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	5	-	-	-	-	-	-	-	-	-	-
305	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Interest received	-	N.A.	6	-	-	-	-	-	-	-	-	-	-	-
306	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received	-	N.A.	126	-	-	-	-	-	-	-	-	-	-	-
307	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Interest received	-	N.A.	15	-	-	-	-	-	-	-	-	-	-	-
308	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Interest received	-	N.A.	10	-	-	-	-	-	-	-	-	-	-	-
309	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Interest received	-	N.A.	76	-	-	-	-	-	-	-	-	-	-	-
310	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Loan	-	N.A.	1	-	-	-	-	-	Loan	6 M SOFR + 50bps	1 Year	Unsecured	Business Purpose	













**Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]**  
Disclosure of related party transactions for the half year/ six months ended September 30, 2023

Amount in INR Million except stated otherwise

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of Related Party Transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans/ investments				Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
391	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	0	-	-	-								

**Notes:**

- 1 Amount mentioned as 0 denotes value less than INR 1 Million.
- 2 Opening and closing balance are not given where there was no transaction of Investment during the half year ended September 30, 2023.
- 3 Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.
- 4 Loans given and repaid within reporting period is not disclosed.